CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 217 filers reported holding CLOVIS ONCOLOGY INC in Q2 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $124,000 | -22.5% | 28,000 | 0.0% | 0.00% | – |
Q2 2021 | $160,000 | -14.4% | 28,000 | 0.0% | 0.00% | -100.0% |
Q1 2021 | $187,000 | +52.0% | 28,000 | 0.0% | 0.00% | – |
Q4 2020 | $123,000 | +29.5% | 28,000 | +233.8% | 0.00% | -100.0% |
Q4 2019 | $95,000 | -12.0% | 8,389 | -68.9% | 0.00% | 0.0% |
Q3 2019 | $108,000 | -82.5% | 26,989 | -40.8% | 0.00% | -66.7% |
Q2 2019 | $616,000 | -29.3% | 45,589 | +87.4% | 0.00% | -40.0% |
Q1 2019 | $871,000 | +134.8% | 24,333 | +17.9% | 0.01% | +150.0% |
Q4 2018 | $371,000 | -57.4% | 20,633 | -15.2% | 0.00% | -60.0% |
Q3 2018 | $871,000 | -18.5% | 24,333 | +2.5% | 0.01% | -28.6% |
Q2 2018 | $1,069,000 | -14.9% | 23,750 | 0.0% | 0.01% | -22.2% |
Q1 2018 | $1,256,000 | -63.4% | 23,750 | -50.3% | 0.01% | -66.7% |
Q4 2017 | $3,431,000 | 0.0% | 47,800 | 0.0% | 0.03% | 0.0% |
Q3 2017 | $3,431,000 | +13.7% | 47,800 | +45.7% | 0.03% | +12.5% |
Q2 2017 | $3,018,000 | +46.5% | 32,800 | 0.0% | 0.02% | +26.3% |
Q1 2017 | $2,060,000 | +88.0% | 32,800 | +32.8% | 0.02% | +58.3% |
Q4 2016 | $1,096,000 | +38.7% | 24,700 | +8.3% | 0.01% | +33.3% |
Q3 2016 | $790,000 | +130.3% | 22,800 | 0.0% | 0.01% | +125.0% |
Q2 2016 | $343,000 | +8.2% | 22,800 | +38.2% | 0.00% | 0.0% |
Q1 2016 | $317,000 | -52.5% | 16,500 | -14.9% | 0.00% | -50.0% |
Q4 2015 | $667,000 | -62.2% | 19,400 | +1.0% | 0.01% | -63.6% |
Q3 2015 | $1,766,000 | +21.5% | 19,200 | +16.0% | 0.02% | +29.4% |
Q2 2015 | $1,454,000 | +22.8% | 16,550 | +3.8% | 0.02% | +13.3% |
Q1 2015 | $1,184,000 | +17.9% | 15,950 | -12.4% | 0.02% | +15.4% |
Q4 2014 | $1,004,000 | +11.2% | 18,200 | -8.5% | 0.01% | +8.3% |
Q3 2014 | $903,000 | +11.9% | 19,900 | +2.1% | 0.01% | 0.0% |
Q2 2014 | $807,000 | -44.0% | 19,500 | -6.2% | 0.01% | -47.8% |
Q1 2014 | $1,441,000 | +26.8% | 20,800 | +7.5% | 0.02% | +21.1% |
Q4 2013 | $1,136,000 | +10.9% | 19,350 | +14.8% | 0.02% | +5.6% |
Q3 2013 | $1,024,000 | +13.1% | 16,850 | +26.7% | 0.02% | 0.0% |
Q2 2013 | $905,000 | – | 13,300 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |